FDA Clears First Reversal Agent for Rivaroxaban, Apixaban Anticoagulants | DAIC
No evidence to support routine blood monitoring for new oral anticoagulants - apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto) | myVMC
Year-end approval clears Eliquis for US launch - MM+M - Medical Marketing and Media